Toxicology

The Gene Therapy for Muscular Disorders Summit took place in April this year, and is the field’s only industry-focused event specifically designed to help gene therapy developers successfully target the muscle. With a disease-agnostic agenda, but highlighting novel research in Duchenne’s (DMD), Limb-Girdle (LGMD), Pompe Disease and X-Linked Myotubular Myopathy (XLMTM), the expert industry speakers from the likes of Solid Biosciences, Sarepta Therapeutics, Astellas Gene Therapies and Pfizer spent 4-days discussing the fields hottest topics from navigating toxicity to state-of-the-art muscular targeting.

ASCPT Annual Meeting attendees include clinical pharmacologists, pharmacists, and others whose primary interest is to promote and advance the science of human pharmacology and therapeutics.

The American Society for Clinical Pathology (ASCP) is the world’s largest professional membership organization for pathologists and laboratory professionals. With more than 100,000 members, the society’s influence has guided the application and evolution of the pathology and laboratory medicine specialty since 1922. The pre-eminent event for the entire laboratory team, the ASCP Annual Meeting is known for bringing together pathologists, laboratory professionals, pathology residents, and more, in a learning-focused setting you can only find once per year.

This unique event brings together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers to discuss advances in next-generation oligonucleotide and precision therapeutics throughout the drug development process.

The World Drug Safety Congress Europe is empowering patients, physicians, pharma, biotech and consumers to make the best drug safety decisions. We’ll bring together 600+ key thought leaders to explore these challenges within pharmacovigilance. Explore the use of big data and AI in pharmacovigilance, examine benefit-risk management strategies and patient-centric approaches; discuss how you can tackle the challenges of social media and drug safety legislation globally.

The Scientific Program features a diverse range of scientific sessions organized into two concurrent themed tracks covering issues such as Novel In Vitro and In Silico Assays to Predict Human Safety, In Vivo and Ex vivo Case Studies For Safety, Debate on the “Value” of Primary Tissue and In Vivo Studies and are disease Models Relevant in Safety Pharmacology, Macro Molecules Science: Antibodies, Oligo, and Peptides, Translation Beyond FIH Exposure Response Models, Macro Molecules Science: Gene therapy, Cell Therapy, mRNA and PROTAC, Derisking and Risk Mitigation Strategies, Clinical Cardiology, and much more! This will ensure attendees can stay abreast of new content and developments in key areas of interest. 

With more than 6,500 toxicologists from all over the world expected to attend, opportunities for networking and finding new collaborators are abundant—from the Scientific Sessions and other daytime events through the evening receptions. Research organizations, government agencies, drug developers, regulatory authorities, academic institutions, laboratory and medical suppliers, or consultants are encouraged to exhibit at ToxExpo.

Toxicology – multidisciplinary science leading to safer and sustainable life – Our mission is to foster the science and education of toxicology, and influence regulatory and policy frameworks to promote the safety of humans, animals and the environment, and protect global health.

Hundreds of clinical trials using AAV are underway, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline, the need to administer high doses, the clinical holds placed on gene therapy trials, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that’s fit for purpose! In this setting, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology, pharmacology, non-clinical study leads, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays.Join us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics, Ask Bio, Eli Lilly, Takeda, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies, learn how clinical safety signals have changed how companies are approaching their pipeline progression, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.

The 2nd Annual Next Generation Gene Therapy Vectors Summit is dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors.Industry pioneers from cutting edge biopharma and world-leading academic vectorology groups including Voyager Therapeutics, Spark Therapeutics, Dyno Therapeutics, Chameleon Biosciences, BioMarin and more will share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely. Spanning a range of delivery approaches from cutting-edge AAV capsid optimisation, utilising lenti and other viral vectors, to innovative non-viral gene therapy approaches, this comprehensive event will enable you to reduce immunogenicity, improve tissue targeting, simplify manufacturing and enhance the safety profile of your approach. Everything in gene therapy starts with delivery, so join this definitive, niche conference to delve into the details of vector design, engineering and optimization case studies, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before.